MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 232 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.33 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $4,342 | -52.5% | 15,496 | -54.7% | 0.00% | -66.7% |
| Q1 2024 | $9,139 | +3.0% | 34,223 | -10.8% | 0.00% | 0.0% |
| Q4 2023 | $8,874 | +130.0% | 38,354 | +45.2% | 0.00% | +50.0% |
| Q3 2023 | $3,858 | -38.1% | 26,410 | -2.2% | 0.00% | -50.0% |
| Q2 2023 | $6,235 | -64.7% | 26,991 | -63.0% | 0.00% | -50.0% |
| Q1 2023 | $17,669 | -30.7% | 72,935 | -17.0% | 0.01% | -27.3% |
| Q4 2022 | $25,503 | -99.1% | 87,868 | +102.4% | 0.01% | +266.7% |
| Q3 2022 | $2,821,000 | +415.7% | 43,415 | +468.3% | 0.00% | – |
| Q2 2022 | $547,000 | -40.2% | 7,639 | -18.0% | 0.00% | -100.0% |
| Q1 2022 | $914,000 | -63.2% | 9,315 | -68.2% | 0.00% | – |
| Q4 2021 | $2,482,000 | +68.2% | 29,292 | +58.2% | 0.00% | -100.0% |
| Q3 2021 | $1,476,000 | -8.5% | 18,513 | +11.8% | 0.00% | 0.0% |
| Q2 2021 | $1,613,000 | -28.1% | 16,561 | -13.6% | 0.00% | 0.0% |
| Q1 2021 | $2,242,000 | +25.8% | 19,168 | +19.6% | 0.00% | 0.0% |
| Q4 2020 | $1,782,000 | -13.0% | 16,029 | -7.1% | 0.00% | 0.0% |
| Q3 2020 | $2,049,000 | -8.9% | 17,262 | -13.0% | 0.00% | -50.0% |
| Q2 2020 | $2,248,000 | +82.9% | 19,837 | +7.8% | 0.00% | +100.0% |
| Q1 2020 | $1,229,000 | +1.7% | 18,398 | +38.9% | 0.00% | 0.0% |
| Q4 2019 | $1,208,000 | +215.4% | 13,244 | +197.8% | 0.00% | – |
| Q3 2019 | $383,000 | -27.5% | 4,448 | -11.8% | 0.00% | – |
| Q2 2019 | $528,000 | -75.0% | 5,041 | -70.1% | 0.00% | -100.0% |
| Q1 2019 | $2,110,000 | -54.9% | 16,848 | -59.4% | 0.00% | -75.0% |
| Q4 2018 | $4,678,000 | -28.2% | 41,502 | +36.4% | 0.00% | 0.0% |
| Q3 2018 | $6,516,000 | -3.1% | 30,430 | +26.5% | 0.00% | -33.3% |
| Q2 2018 | $6,726,000 | +76.3% | 24,046 | -26.4% | 0.01% | +100.0% |
| Q1 2018 | $3,815,000 | +2952.0% | 32,670 | +2293.4% | 0.00% | – |
| Q4 2017 | $125,000 | +3025.0% | 1,365 | +1307.2% | 0.00% | – |
| Q3 2017 | $4,000 | -50.0% | 97 | -80.0% | 0.00% | – |
| Q2 2017 | $8,000 | – | 485 | +12025.0% | 0.00% | – |
| Q1 2017 | $0 | – | 4 | 0.0% | 0.00% | – |
| Q4 2016 | $0 | – | 4 | 0.0% | 0.00% | – |
| Q3 2016 | $0 | – | 4 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 73,487 | $17,003,422 | 28.29% |
| Tao Capital Management LP | 130,529 | $30,202 | 27.63% |
| Paulson & Co. | 1,105,741 | $255,846,353 | 23.09% |
| AlpInvest Partners B.V. | 211,488 | $48,934,093 | 11.18% |
| Bain Capital Life Sciences Investors, LLC | 324,619 | $75,110,344 | 7.20% |
| Avoro Capital Advisors LLC | 1,888,888 | $437,050,905 | 6.04% |
| Propel Bio Management, LLC | 30,032 | $6,948,804 | 5.76% |
| Baker Brothers Advisors | 1,969,798 | $455,771,861 | 5.19% |
| Rosalind Advisors, Inc. | 25,000 | $5,784,500 | 4.76% |
| TCG Crossover Management, LLC | 179,917 | $41,629,195 | 4.62% |